Cart
sales@molnova.com
LMD-A
CAS No. 850330-77-7
LMD-A( CCR8 antagonist LMD-A )
Catalog No. M16174 CAS No. 850330-77-7
LMD-A (CCR8 antagonist LMD-A) is a highly potent, small molecule antagonist of chemokine receptor CCR8 with EC50 of 2.5 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1773 | Get Quote |
|
| 50MG | 3582 | Get Quote |
|
| 100MG | 4950 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLMD-A
-
NoteResearch use only, not for human use.
-
Brief DescriptionLMD-A (CCR8 antagonist LMD-A) is a highly potent, small molecule antagonist of chemokine receptor CCR8 with EC50 of 2.5 nM.
-
DescriptionLMD-A (CCR8 antagonist LMD-A) is a highly potent, small molecule antagonist of chemokine receptor CCR8 with EC50 of 2.5 nM; inhibits 10 nM CCL1-induced activation of CCR8 with EC50 of 12 nM, inhibits 4DE4 cells cell migration induced by 3 nM CCL1 with EC50 of 0.58 nM.
-
In Vitro——
-
In Vivo——
-
SynonymsCCR8 antagonist LMD-A
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number850330-77-7
-
Formula Weight508.637
-
Molecular FormulaC27H32N4O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NC1=C2C=CC=C(S(=O)(N[C@H]3[C@H](C)CN(C([C@H](C)N)=O)CC3)=O)C2=CC=C1)C4=CC=CC=C4C
-
Chemical NameN-(5-(N-((3R,4R)-1-(L-alanyl)-3-methylpiperidin-4-yl)sulfamoyl)naphthalen-1-yl)-2-methylbenzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rummel PC, et al. Br J Pharmacol. 2012 Nov;167(6):1206-17.
2. Barington L, et al. J Biol Chem. 2016 Jul 29;291(31):16208-20.
molnova catalog
related products
-
Vicriviroc maleate
A potent, highly selective, and orally bioavailable CCR5 antagonist with Ki of 2.5 nM.
-
CCX140
A potent, selective, orally bioavailable CCR2 antagonist with Kd of 2.3 nM for hCCR2.
-
E 6130
A potent, selective, orally available CX3C chemokine receptor 1 (CX3CR1) modulator that inhibits the fractalkine-induced chemotaxis of human peripheral blood NK cells with IC50 of 4.9 nM.
